These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 9467533

  • 1. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
    Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers CY.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):309-19. PubMed ID: 9467533
    [Abstract] [Full Text] [Related]

  • 2. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
    Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
    [Abstract] [Full Text] [Related]

  • 3. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY.
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [Abstract] [Full Text] [Related]

  • 4. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G, Wouters P, Carlsson L, Baxter RC, Bouillon R, Bowers CY.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [Abstract] [Full Text] [Related]

  • 5. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R.
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
    Van den Berghe G, Wouters P, Bowers CY, de Zegher F, Bouillon R, Veldhuis JD.
    Eur J Endocrinol; 1999 Jan; 140(1):17-22. PubMed ID: 10037246
    [Abstract] [Full Text] [Related]

  • 7. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
    Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R.
    Clin Endocrinol (Oxf); 2002 May; 56(5):655-69. PubMed ID: 12030918
    [Abstract] [Full Text] [Related]

  • 8. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [Abstract] [Full Text] [Related]

  • 9. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N, Evans WS, Bowers CY, Veldhuis JD.
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [Abstract] [Full Text] [Related]

  • 10. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G, Weekers F, Baxter RC, Wouters P, Iranmanesh A, Bouillon R, Veldhuis JD.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [Abstract] [Full Text] [Related]

  • 11. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.
    Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R.
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1311-23. PubMed ID: 10199772
    [Abstract] [Full Text] [Related]

  • 12. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
    Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL.
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
    [Abstract] [Full Text] [Related]

  • 13. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD.
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [Abstract] [Full Text] [Related]

  • 14. Growth hormone secretagogues in critical illness.
    Van den Berghe G.
    Horm Res; 1999 May; 51 Suppl 3():21-8. PubMed ID: 10592440
    [Abstract] [Full Text] [Related]

  • 15. Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness.
    Weekers F, Michalaki M, Coopmans W, Van Herck E, Veldhuis JD, Darras VM, Van den Berghe G.
    Endocrinology; 2004 Jan; 145(1):205-13. PubMed ID: 14551231
    [Abstract] [Full Text] [Related]

  • 16. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
    Huhn WC, Hartman ML, Pezzoli SS, Thorner MO.
    J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
    [Abstract] [Full Text] [Related]

  • 17. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2.
    Debaveye Y, Ellger B, Mebis L, Van Herck E, Coopmans W, Darras V, Van den Berghe G.
    Endocrinology; 2005 Dec; 146(12):5604-11. PubMed ID: 16150898
    [Abstract] [Full Text] [Related]

  • 18. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.
    Veldhuis JD, Bowers CY.
    Am J Physiol Endocrinol Metab; 2009 May; 296(5):E1085-92. PubMed ID: 19240251
    [Abstract] [Full Text] [Related]

  • 19. Secretory mechanisms of growth hormone (GH)-releasing peptide-, GH-releasing hormone-, and thyrotropin-releasing hormone-induced GH release in patients with acromegaly.
    Hanew K, Utsumi A, Tanaka A, Ikeda H, Yokogoshi Y.
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3578-83. PubMed ID: 9768668
    [Abstract] [Full Text] [Related]

  • 20. Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism.
    Veldhuis JD, Keenan DM, Bailey JN, Miles JM, Bowers CY.
    Eur J Endocrinol; 2009 Aug; 161(2):293-300. PubMed ID: 19458139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.